TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01588990
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive leucovorin 400 mg/m\^2 IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B). Investigators may elect to chose low dose of leucovorin (either 20 mg/m\^2 or 50 mg total dose).
Study: NCT01588990
Drug: 5-Fluouracil
Normalized name: Fluouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Participants will receive 5-fluouracil loading dose of 400 mg/m\^2 IV on Day 1 followed by 2400 mg/m\^2 continuous IV infusion over 46 hours Day 1 (Alternative Phase A treatment and Phase B).
Study: NCT02500212
Drug: ENVARSUS®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02500212
Drug: ADVAGRAF®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01324479
Drug: INC280
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00346229
Drug: lyso-thermosensitive liposomal doxorubicin(Thermodox)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00781859
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo intravitreal injection
Study: NCT01029847
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: sc. inj. placebo every other week, week 0, 2, and 4. Sc. inj. adalimumab 40 mg every other week from week 6.~At week 24, clinical non-responders (not fulfilling primary outcome measure) were allowed treatment with other drugs, following local treatment guidelines.
Study: NCT03422666
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00621140
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT01371734
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects randomized to the Placebo treatment arm will receive placebo tablets
Study: NCT02578186
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL at bedtime
Study: NCT00461123
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
Study: NCT02710097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
Study: NCT02710097
Drug: Active Oral Ethanol
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
Study: NCT02710097
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No active cannabinoids. Administered over 20 minutes via a vaporizer.
Study: NCT02951351
Drug: Proparacaine
Normalized name: proparacaine
DrugBank: Proparacaine (DB00807)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
Study: NCT01561456
Drug: AXL1717
Approvals — FDA: no, EMA: no, PMDA: no
Description: AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
Study: NCT01965158
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet taken orally once a day
Study: NCT01885013
Drug: Metformin + Myocet + Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Myocet + Cyclophosphamide:~Metformin 1000 mg, 2 times daily per os\*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.~\* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day.
Study: NCT01829893
Drug: GL2701 capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral medication with 240 mL water
Study: NCT03055546
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo
Study: NCT04860856
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml of normal saline
Study: NCT00460317
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg QD orally every day
Study: NCT00605566
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of \> 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally.
Study: NCT02546154
Drug: 10% Iron Isomaltoside 1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard clinical practice and following the Monofer® label (SPC)
Study: NCT03022838
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
Study: NCT00453479
Drug: GSK233705B
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02104505
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Safflower oil capsules
Study: NCT03912974
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: see 'arm description'
Study: NCT03486925
Drug: placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: intranasal administration of placebo
Study: NCT00885352
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
Study: NCT02549417
Drug: KHK7580
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration
Study: NCT03953456
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a coated tablet for oral administration, once daily
Study: NCT00238953
Drug: Enteric-Coated Mycophenolate Sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01885013
Drug: Myocet + Cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocet + Cyclophosphamide:~Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles
Study: NCT04486508
Drug: intermediate dose Enoxaparin/ unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermediate dose anticoagulation according to creatinine clearance and weight
Study: NCT04486508
Drug: standard prophylactic dose Enoxaparin/ unfractionated heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard prophylaxis anticoagulation according to creatinine clearance and weight
Study: NCT04229030
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vehicle of RZL-012 drug product
Study: NCT03740204
Drug: 17-β estradiol transdermal patches with cyclic progesterone
Normalized name: 17α-progesterone
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 17-β estradiol transdermal patches (100 mcg 17-β estradiol/day) with cyclic progesterone (200 mg micronized progesterone daily for 12 days every month)
Study: NCT03740204
Drug: Placebo patch and pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo patch and pill
Study: NCT04486508
Drug: Matched placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched placebo to atorvastatin 20 mg
Study: NCT03232710
Drug: Bosiqing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole Orally disintegrating tablets 10mg
Study: NCT00511836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
Study: NCT04742062
Drug: ApTOLL
Approvals — FDA: no, EMA: no, PMDA: no
Description: ApTOLL is a Toll-like receptor 4 (TLR4) antagonist, a receptor that is involved in innate immune responses but also responds to tissue damage, and therefore it is directly involved in a large number of diseases where the inflammatoryy response is involved. ApTOLL has demonstrated specific binding to human TLR4 as well as a TLR4 antagonistic effect, reducing inflammation and improving outcome after different disease models.
Study: NCT00864526
Drug: COMBONOX® tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
Study: NCT02457442
Drug: Propofol and Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High propofol and low remifentanil, changing remifentanil (up-and-down method)
Study: NCT02457442
Drug: Propofol and Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low propofol and high remifentanil, changing propofol (up-and-down method)
Study: NCT02457442
Drug: Sevoflurane and Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
Study: NCT02457442
Drug: Sevoflurane and Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
Study: NCT02457442
Drug: SPR2
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.~Changing Sevoflurane for skin incision.
Study: NCT02354547
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
Study: NCT03871621
Drug: Diabetes Medicines
Normalized name: Diabetic Tussin EX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-diabetic medications except SGLT2 inhibitors
Study: NCT03177109
Drug: 5% fluoride varnish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applied topically as a coating at single point in time
Study: NCT02252458
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01397500
Drug: Testosterone undecannoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecannoate administered twice (6 week Interval) im by investigator.
Study: NCT01085812
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo to be given orally, in capsule form, once daily.
Study: NCT01168336
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo
Study: NCT00003912
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03870412
Drug: PEG-rhG-CSF
Approvals — FDA: no, EMA: no, PMDA: no
Description: The test drug PEG-rhG-CSF was administered prophylactically to elderly lymphoma patients who met the inclusion/exclusion criteria 24-72 hours after chemotherapy.
Study: NCT04055415
Drug: Conventional drug therapy（expectorant，bronchodilator）
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional drug therapy（expectorant，bronchodilator）
Study: NCT01401114
Drug: E2/LNG oral (Wellnara, BAY86-5029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
Study: NCT00941642
Drug: placebo control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
Study: NCT04128800
Drug: Apatinib S-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: apatinib 250 mg PO qd; S-1 40 mg PO in the morning and 60 mg PO in the evening; 14 days in combination, 21 days in a cycle.
Study: NCT00365274
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV 750 mg/m\^2 day 1
Study: NCT00365274
Drug: Doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given 50 mg/m\^2 IV day 1
Study: NCT01089309
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spironolactone orally, at a dose of 50 mg/day for 12 months
Study: NCT00192023
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02173145
Drug: azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
Study: NCT02173145
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be given 3 times a wek over a period of 3 months.
Study: NCT01114672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo once weekly
Study: NCT00934414
Drug: Technosphere Insulin Inhalation Powder
Normalized name: insulin, regular, human Inhalation Powder [Afrezza]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30U
Study: NCT01672593
Drug: Anti-Bacterial Agents
Normalized name: INVESTIGATIONAL ANTI-BACTERIAL DRUGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
Study: NCT00429897
Drug: Bendroflumethiazide 2.5mg - 5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00429897
Drug: Amiloride 20-40mg
Normalized name: amiloride 20 MG / furosemide 40 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00429897
Drug: Spironolactone 50-100mg
Normalized name: spironolactone 100 MG
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00429897
Drug: Frusemide 20-40mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00429897
Drug: Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04049903
Drug: MP0310
Approvals — FDA: no, EMA: no, PMDA: no
Description: MP0310 will be examined for safety, tolerability, PK, and PD activity in subjects with advanced solid tumors
Study: NCT03748836
Drug: ALPN-101
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of ALPN-101 delivered via intravenous or subcutaneous injection. Ascending dose levels will be evaluated.
Study: NCT03748836
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single or multiple doses of placebo delivered via intravenous or subcutaneous injection, matched to ALPN-101 cohorts.
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose group 1
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose group 2
Study: NCT01133574
Drug: SLV354 capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: high dose group 2
Study: NCT02205099
Drug: SKL15508
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02205099
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01133574
Drug: Placebo capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo
Study: NCT03900377
Drug: SyB L-0501RI
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: The specified dose of SyB L-0501RI and rituximab will be administered by intravenous rapid infusion over 10 minutes on specified days.
Study: NCT02891044
Drug: BAY987517
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each 50 cm\*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm\*2 test application. (Formulation Code: Z44-040)
Study: NCT03885804
Drug: Quadratus lamborum dexmedetomidine perineural group(
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive quadratus lamborum block on the same surgical side then1μ g/kg diluted to 2 mL with 0.9% saline added to 0.5 ml/kg of 0.25% bupivacaine in addition to saline infusion 1ml/kg IV loading dose followed by by 0.5 ml/kg/h infusion maintenance dose till the end of surgery.
Study: NCT03324113
Drug: SAR408701
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Study: NCT02792647
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT00104637
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg po tid
Study: NCT01313624
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match AZLI administered via nebulizer three times daily
Study: NCT01742091
Drug: LY2541546 - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01742091
Drug: Placebo - SC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT01742091
Drug: Placebo - IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered IV
Study: NCT01072968
Drug: BF2.649
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day in the morning before the breakfast
Study: NCT01072968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 capsule per day in the morning before the breakfast
Study: NCT02281968
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
Study: NCT02281968
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01598207
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg BID, orally for 1 month
Study: NCT02580240
Drug: Hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
Study: NCT01444872
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion
Study: NCT02277808
Drug: 500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)
Normalized name: amikacin
DrugBank: Amikacin (DB00479)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00176410
Drug: fluvastatin
Normalized name: Fluvastatin
DrugBank: Fluvastatin (DB01095)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 40mg fluvastatin daily
Study: NCT03049345
Drug: Radioactive Tracers
Approvals — FDA: no, EMA: no, PMDA: no
Description: see above
Study: NCT02649361
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. qd
Study: NCT00616330
Drug: clindamycin phosphate/butoconazole nitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: semi solid, single dose
Study: NCT00616330
Drug: clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: semi solid, single dose
Study: NCT00966030
Drug: MK0974 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 280 mg tablet in one of two treatment periods
Study: NCT00966030
Drug: Comparator: MK0974 liquid filled capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK0974 300 mg liquid filled capsule in one of two treatment periods
Study: NCT00027976
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00027976
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03043482
Drug: Single VS-105/placebo to healthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
Study: NCT03043482
Drug: Multiple VS-105/placebo to healthy
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
Study: NCT03043482
Drug: Multiple VS-105/placebo to HD subjects
Approvals — FDA: no, EMA: no, PMDA: no
Description: In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
Study: NCT02893098
Drug: Humia inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single injection of 3mL Humia inj.~Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks
Study: NCT02893098
Drug: High hyal Plus inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks